Intercept Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Intercept Pharmaceuticals

28/02/2023 15:27

* Intercept Pharmaceuticals Inc  ICPT.OQ   ICPT.O  is
expected
to show a fall in quarterly revenue when it reports  results on
March 2. 
    * The Morristown New Jersey-based  company is expected to
report 
a 15.5% decrease in revenue to $78.076 million from $92.4
million a year ago, according to the mean estimate from 16
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Intercept
Pharmaceuticals
Inc is for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 9
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Intercept
Pharmaceuticals Inc is $21​, above​ its last closing price
of $19.82. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  5.79        4.61       7.80      Beat    69.3
 Jun. 30 2022  -0.39       -0.49      -0.68     Missed  -39.5
 Mar. 31 2022  -0.80       -0.90      -0.58     Beat    35.7​
 Dec. 31 2021  -0.98       -1.10      -1.23     Missed  -12.1
 ​​Sep.        -1.06       -1.09      -0.63     Beat    42.2
 30 2021                                                
 Jun. 30 2021  -1.20       -1.22      -0.33     Beat    72.9​
 Mar. 31 2021  -1.46       -1.44      -1.22     Beat    15.4
 Dec. 31 2020  -1.43       -1.47      -1.58     Missed  -7.2
 This summary was machine generated February 28 at 15:27 GMT. 
All figures in US dollars  unless otherwise stated